BioStock: Lipum seeks patent protecting inflammation-driven cancer treatment
Lipum has submitted an international patent application for SOL-116 as a treatment for inflammation-driven cancer. The patent application is based on the company’s research demonstrating that SOL-116 inhibits the growth of cancer cells by blocking the target protein BSSL. Additionally, studies on breast cancer patients indicate that high expression of BSSL correlates with a poor prognosis and shorter survival.
Read the full article at biostock.se:
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se